Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.
Type:
Grant
Filed:
October 28, 2020
Date of Patent:
January 16, 2024
Assignee:
Principia Biopharma Inc.
Inventors:
Abu J. Ferdous, Mohammad R. Masjedizadeh, Wu Lin
Abstract: Solid forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and solid forms thereof are also disclosed.
Type:
Application
Filed:
May 16, 2023
Publication date:
December 14, 2023
Applicant:
Principia Biopharma Inc.
Inventors:
Kolbot By, Katherine Chu, Mohammad R. Masjedizadeh, Pasit Phiasivongsa, Jiang Zhu
Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Type:
Grant
Filed:
November 16, 2021
Date of Patent:
November 28, 2023
Assignee:
Principia Biopharma Inc.
Inventors:
Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
Abstract: Crystalline forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
Type:
Grant
Filed:
January 21, 2021
Date of Patent:
November 14, 2023
Assignee:
Principia Biopharma Inc.
Inventors:
Pasit Phiasivongsa, Kolbot By, Jean Baum
Abstract: Disclosed herein are topical pharmaceutical compositions, e.g., for application to the skin of a subject, comprising (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile (Compound (I)), methods of making the same, and methods of using the same, e.g., for the treatment of various dermatological disorders.
Type:
Application
Filed:
January 12, 2023
Publication date:
September 7, 2023
Applicant:
Principia Biopharma Inc.
Inventors:
Katherine Chu, Jyoti Wadhwa, Jason Carbol, Pasit Phiasivongsa, Claire Langrish, Dolca Thomas
Abstract: Solid forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and solid forms thereof are also disclosed.
Abstract: Crystalline forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of inhibiting BTK using the same, and methods for making crystalline forms of Compound (I) are also disclosed.
Type:
Grant
Filed:
January 7, 2021
Date of Patent:
June 6, 2023
Assignee:
Principia Biopharma Inc.
Inventors:
Pasit Phiasivongsa, Jiang Zhu, Kolbot By, Mohammad Reza Masjedizadeh
Abstract: Methods of treating a disease chosen from acute respiratory distress syndrome, sepsis, sepsis induced acute lung injury, diffuse alveolar damage, macrophage activation syndrome, secondary hemophagocytic lymphohistiocytosis, cytokine release syndrome, and systemic inflammatory response syndrome in a mammal using a therapeutically effective amount of a small molecular BTK inhibitor are disclosed.
Abstract: The present disclosure provides compounds that are tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of BTK such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Abstract: Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising at least one compound chosen from PRN1008 and pharmaceutically acceptable salts thereof are also disclosed.
Type:
Application
Filed:
September 16, 2022
Publication date:
April 20, 2023
Applicant:
Principia Biopharma Inc.
Inventors:
Steven Gourlay, Ann Neale, Philip Nunn, Claire Langrish, Olga Bandman, Dolca Thomas
Abstract: Disclosed herein are topical pharmaceutical compositions, e.g., for application to the skin of a subject, comprising (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile (Compound (I)), methods of making the same, and methods of using the same, e.g., for the treatment of various dermatological disorders.
Type:
Grant
Filed:
January 7, 2021
Date of Patent:
February 21, 2023
Assignee:
Principia Biopharma Inc.
Inventors:
Katherine Chu, Jyoti Wadhwa, Jason Carbol, Pasit Phiasivongsa, Claire Langrish, Dolca Thomas
Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
May 24, 2022
Publication date:
November 24, 2022
Applicant:
Principia Biopharma, Inc.
Inventors:
Mohammad Reza Masjedizadeh, Steven Gourlay
Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
October 5, 2020
Date of Patent:
June 28, 2022
Assignee:
Principia Biopharma Inc.
Inventors:
Mohammad Reza Masjedizadeh, Steven Gourlay
Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Type:
Application
Filed:
November 16, 2021
Publication date:
March 10, 2022
Applicant:
Principia Biopharma Inc.
Inventors:
Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Type:
Grant
Filed:
November 14, 2018
Date of Patent:
January 18, 2022
Assignee:
Principia Biopharma Inc.
Inventors:
Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
Abstract: Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Type:
Grant
Filed:
January 16, 2018
Date of Patent:
October 26, 2021
Assignee:
Principia Biopharma Inc.
Inventors:
Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
Abstract: The present disclosure provides compounds of formula (I) that are tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of BTK such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.